Loading…

Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma

A major roadblock prohibiting effective cellular immunotherapy of pancreatic ductal adenocarcinoma (PDAC) is the lack of suitable tumor-specific antigens. To address this challenge, here we combine flow cytometry screenings, bioinformatic expression analyses and a cyclic immunofluorescence platform....

Full description

Saved in:
Bibliographic Details
Published in:Nature communications 2021-03, Vol.12 (1), p.1453-18, Article 1453
Main Authors: Schäfer, Daniel, Tomiuk, Stefan, Küster, Laura N., Rawashdeh, Wa’el Al, Henze, Janina, Tischler-Höhle, German, Agorku, David J., Brauner, Janina, Linnartz, Cathrin, Lock, Dominik, Kaiser, Andrew, Herbel, Christoph, Eckardt, Dominik, Lamorte, Melina, Lenhard, Dorothee, Schüler, Julia, Ströbel, Philipp, Missbach-Guentner, Jeannine, Pinkert-Leetsch, Diana, Alves, Frauke, Bosio, Andreas, Hardt, Olaf
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A major roadblock prohibiting effective cellular immunotherapy of pancreatic ductal adenocarcinoma (PDAC) is the lack of suitable tumor-specific antigens. To address this challenge, here we combine flow cytometry screenings, bioinformatic expression analyses and a cyclic immunofluorescence platform. We identify CLA, CD66c, CD318 and TSPAN8 as target candidates among 371 antigens and generate 32 CARs specific for these molecules. CAR T cell activity is evaluated in vitro based on target cell lysis, T cell activation and cytokine release. Promising constructs are evaluated in vivo. CAR T cells specific for CD66c, CD318 and TSPAN8 demonstrate efficacies ranging from stabilized disease to complete tumor eradication with CD318 followed by TSPAN8 being the most promising candidates for clinical translation based on functionality and predicted safety profiles. This study reveals potential target candidates for CAR T cell based immunotherapy of PDAC together with a functional set of CAR constructs specific for these molecules. There is an unmet clinical need to identify therapeutic options for the treatment of pancreatic cancer (PDAC). Here the authors present a systematic screening approach for the identification of potential PDAC cell surface target candidates for CAR-T cell based immunotherapy, followed by their functional validation in preclinical models.
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-021-21774-4